We are thrilled to provide a new therapy that further extends the lives of patients with metastatic colorectal cancer and look forward to working with European health authorities to ensure patients have access to ZALTRAP.In Europe, colorectal cancer is the most common cancer in both men and women and is the second leading cause of cancer death.